Puriblood Medical Co., Ltd.
Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan. The company offers leukoreduction, cell separation, and P-Tex, an advanced anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsi… Read more
Puriblood Medical Co., Ltd. (6847) - Total Liabilities
Latest total liabilities as of June 2025: NT$90.33 Million TWD
Based on the latest financial reports, Puriblood Medical Co., Ltd. (6847) has total liabilities worth NT$90.33 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Puriblood Medical Co., Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Puriblood Medical Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Puriblood Medical Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Puriblood Medical Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eastern Star Real Estate Public Company Limited
BK:ESTAR
|
Thailand | ฿2.92 Billion |
|
Pantera Silver Corp.
PINK:PNTRF
|
USA | $203.90K |
|
Carriesoft Co. Ltd
KQ:317530
|
Korea | ₩8.75 Billion |
|
Foresta Group Holdings Ltd
AU:FGH
|
Australia | AU$2.89 Million |
|
Donegal Investment Group PLC
IR:DQ7A
|
Ireland | €14.60 Million |
|
Jeil Pharm
KO:002620
|
Korea | ₩400.33 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Puriblood Medical Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Puriblood Medical Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Puriblood Medical Co., Ltd. (2019–2024)
The table below shows the annual total liabilities of Puriblood Medical Co., Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$83.75 Million | -0.71% |
| 2023-12-31 | NT$84.35 Million | -3.57% |
| 2022-12-31 | NT$87.47 Million | +78.13% |
| 2021-12-31 | NT$49.11 Million | -5.45% |
| 2020-12-31 | NT$51.94 Million | -11.75% |
| 2019-12-31 | NT$58.85 Million | -- |